Axa held its stake in shares of Endologix, Inc. (NASDAQ:ELGX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 962,787 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Axa owned about 1.15% of Endologix worth $4,679,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in ELGX. Teachers Advisors LLC lifted its stake in Endologix by 3.9% during the 4th quarter. Teachers Advisors LLC now owns 130,313 shares of the medical instruments supplier’s stock valued at $745,000 after acquiring an additional 4,851 shares during the period. Nationwide Fund Advisors lifted its stake in Endologix by 34.5% during the 1st quarter. Nationwide Fund Advisors now owns 258,787 shares of the medical instruments supplier’s stock valued at $1,874,000 after acquiring an additional 66,340 shares during the period. Wells Fargo & Company MN lifted its stake in Endologix by 7.6% during the 1st quarter. Wells Fargo & Company MN now owns 157,990 shares of the medical instruments supplier’s stock valued at $1,144,000 after acquiring an additional 11,188 shares during the period. Great West Life Assurance Co. Can lifted its stake in Endologix by 6,604.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 448,025 shares of the medical instruments supplier’s stock valued at $3,249,000 after acquiring an additional 441,342 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its stake in Endologix by 30.0% during the 1st quarter. Parametric Portfolio Associates LLC now owns 89,748 shares of the medical instruments supplier’s stock valued at $650,000 after acquiring an additional 20,685 shares during the period.

Endologix, Inc. (NASDAQ:ELGX) opened at 4.50 on Friday. The stock’s market capitalization is $375.45 million. Endologix, Inc. has a 12-month low of $4.08 and a 12-month high of $13.30. The stock’s 50 day moving average is $4.39 and its 200 day moving average is $5.55.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. The firm had revenue of $48.60 million during the quarter, compared to the consensus estimate of $47.58 million. During the same period last year, the company earned ($0.20) earnings per share. The company’s revenue for the quarter was down 4.6% on a year-over-year basis. Equities research analysts forecast that Endologix, Inc. will post ($0.62) EPS for the current fiscal year.

ELGX has been the subject of several research reports. Stifel Nicolaus restated a “buy” rating and set a $5.50 price objective (up from $5.00) on shares of Endologix in a research note on Monday, June 5th. Canaccord Genuity restated a “hold” rating on shares of Endologix in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price objective on shares of Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. Royal Bank Of Canada restated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research note on Monday, July 31st. Finally, Zacks Investment Research cut shares of Endologix from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. Endologix currently has an average rating of “Hold” and a consensus price target of $6.28.

ILLEGAL ACTIVITY WARNING: “Axa Maintains Holdings in Endologix, Inc. (ELGX)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/17/axa-maintains-holdings-in-endologix-inc-elgx.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.